
Penningtons Manches Cooper advises Titian Software on majority investment from Battery Ventures
The corporate team at Penningtons Manches Cooper has advised shareholders of Titian Software, a leading sample management software solution provider to the life sciences sector, on the significant, majority investment from Battery Ventures, a US technology-focused investment firm.
Titian will use the new funds to support organic growth as well as potential future acquisitions.
Titian’s Mosaic product is the leading sample management software for life science laboratories. Mosaic helps researchers better manage and automate critical processes, allowing its customers to maximise research efficiency and speed up the discovery and delivery of new drugs.
Founded in 1983, Battery Ventures backs companies at all stages, ranging from seed and early to growth and buyout, and invests globally from six strategic locations: Boston; San Francisco, California, Tel Aviv, London, and New York.
Edmund Wilson, Chief Executive Officer and Founder of Titian Software, comments:
“Our new partnership with Battery represents a key inflection point for the company that should allow us to scale even further. With Battery’s help, Titian can better capitalise on the exciting growth opportunities we see ahead in the sample-management sector. I’d like to thank Will Axtell and the team at Penningtons Manches Cooper for their expertise and advice on this strategic deal.”
The corporate team advising Titian Software was led by partner Will Axtell and senior associate Dominique Sabatini with support from associate Lindsay Chadwick. The wider team included support from corporate tax associate Leonie Langley, pensions partner Alison Hills and senior associate Clare Cole, commercial managing associate Edmund Forey and senior associate Susie Hilton Knox, real estate senior associate Giorgia Clements and employment associate Hannah Grayson.
Will Axtell said:
“We are delighted to have advised the team at Titian Software on this important cross-border technology transaction. This demonstrates the strength of our life sciences and technology teams as well as our ability to transact complex and large cross-border corporate deals effectively and at pace. We wish Titian all the best for their exciting future with Battery Ventures.”
More in Solicitors

Penningtons Manches Cooper teams recognised in IAM Patent 1000
It’s great to see our IP, IT and commercial team recognised in the latest IAM Patent 1000. The firm is recommended in the transactions category, while four individual lawyers – Rachel Bradley, Lisa Page, Chris Shelley and Dr Duncan Curley – are also recognised. Rachel, Lisa and Chris are recommended for transactions, and Duncan for […]

Dye & Durham’s Clients Raise Funds for World Housing Charity at...
Dye & Durham was pleased to welcome more than 100 guests from law firms and housing developers across the UK at the annual client summer event held at Henley Royal Regatta, home of the world-famous rowing competition. The event raised money for the World Housing charity. It was sponsored by Thirdfort, a leading supplier of […]

Government announces Freeths appointed to work on new compensation scheme for...
The lawyers that secured the landmark victory in exposing Britain’s largest miscarriage of justice will help hundreds of postmasters by supporting the design and implementation of a new scheme funded by the UK Government.
From this author

Penningtons Manches Cooper teams recognised in IAM Patent 1000
It’s great to see our IP, IT and commercial team recognised in the latest IAM Patent 1000. The firm is recommended in the transactions category, while four individual lawyers – Rachel Bradley, Lisa Page, Chris Shelley and Dr Duncan Curley – are also recognised. Rachel, Lisa and Chris are recommended for transactions, and Duncan for […]

Penningtons Manches Cooper seek Cyber Security Firm of the Year
We’re delighted to sponsor the Cyber Security Firm of the Year category at The Business Magazine’s Thames Valley Tech Awards.

Introducing Chris Shelley, Head of Life Sciences at Penningtons Manches Cooper
Chris Shelley is an IP, commercial and competition partner and Head of Life Sciences at Penningtons Manches Cooper LLP (PMC).